We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+26.99%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$12.5B
AUM Growth
+$844M
Cap. Flow
-$1.62B
Cap. Flow %
-12.95%
Top 10 Hldgs %
33.14%
Holding
137
New
32
Increased
25
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$331M
2
AON icon
Aon
AON
+$321M
3
WUBA
58.com Inc
WUBA
+$256M
4
BMY icon
Bristol-Myers Squibb
BMY
+$217M
5
TIF
Tiffany & Co.
TIF
+$191M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$1.65B
2
CI icon
Cigna
CI
+$142M
3
FIS icon
Fidelity National Information Services
FIS
+$135M
4
GD icon
General Dynamics
GD
+$132M
5
WAB icon
Wabtec
WAB
+$113M

Sector Composition

Rank Sector Weight
1 Healthcare 43.19%
2 Communication Services 20.54%
3 Technology 10.42%
4 Financials 7.52%
5 Consumer Discretionary 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FXI icon
76
PUT
iShares China Large-Cap ETF
FXI
$4.28B
$22.3M 0.18%
+562,500
New +$21.9M
VCYT icon
77
Veracyte
VCYT
$3.4B
$22M 0.18%
850,000
-525,000
-38% -$13.1M
AMRN
78
Amarin Corp
AMRN
$298M
$21.6M 0.17%
156,250
-25,000
-14% -$3.44M
NVTA
79
DELISTED
Invitae Corporation
NVTA
$19.9M 0.16%
656,528
-1,218,772
-65% -$21.3M
ZYME icon
80
Zymeworks
ZYME
$2.05B
$19.8M 0.16%
550,000
-1,200,000
-69% -$44.2M
HWM icon
81
Howmet Aerospace
HWM
$108B
$19M 0.15%
+1,199,186
New +$15.8M
KRYS icon
82
Krystal Biotech
KRYS
$10.3B
$18.6M 0.15%
450,000
+200,000
+80% +$9.62M
PRNB
83
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$17.9M 0.14%
300,000
-84,674
-22% -$5.23M
ZEAL
84
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$17.5M 0.14%
500,000
-250,000
-33% -$8.89M
LQDA icon
85
Liquidia Corp
LQDA
$6.14B
$15.6M 0.12%
+1,850,000
New +$14M
TCDA
86
DELISTED
Tricida, Inc. Common Stock
TCDA
$13.7M 0.11%
500,000
-500,000
-50% -$13.6M
QURE icon
87
uniQure
QURE
$3.36B
$13.5M 0.11%
300,000
+50,000
+20% +$2.95M
RPRX icon
88
Royalty Pharma
RPRX
$27.3B
$13.4M 0.11%
+275,000
New +$13.6M
RC
89
Ready Capital
RC
$311M
$11.7M 0.09%
1,350,226
+82,330
+6% +$560K
SVRA icon
90
Savara
SVRA
$1.15B
$11.1M 0.09%
4,470,964
-354,122
-7% -$862K
CRSP icon
91
CRISPR Therapeutics
CRSP
$5.75B
$11M 0.09%
150,000
-200,000
-57% -$11.7M
CNST
92
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$10.5M 0.08%
+350,000
New +$12.6M
PACB icon
93
Pacific Biosciences
PACB
$420M
$10.3M 0.08%
3,000,000
– –
AKBA icon
94
Akebia Therapeutics
AKBA
$251M
$10.2M 0.08%
750,000
-500,000
-40% -$5.17M
ATTO
95
DELISTED
Atento S.A.
ATTO
$7.71M 0.06%
+2,230,357
New +$11.7M
AKUS
96
DELISTED
Akouos Inc
AKUS
$5.06M 0.04%
+225,000
New +$5.02M
AMTI
97
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$5.03M 0.04%
+200,000
New +$5.05M
RPTX
98
DELISTED
Repare Therapeutics
RPTX
$4.65M 0.04%
+150,000
New +$4.82M
ARYBU
99
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$4.64M 0.04%
+400,000
New +$4.4M
FUSN
100
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$4.37M 0.04%
+250,000
New +$4.35M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2020 Portfolio in Review

As of Q2 2020, Thomas Steyer held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in T-Mobile US worth $360M.

  • Thomas Steyer's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
  • Thomas Steyer added most to Blackstone in Q2 2020, an estimated $125M increase.
  • Thomas Steyer's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
  • Thomas Steyer fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
  • Thomas Steyer's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
  • Thomas Steyer opened 32 new positions and closed 18 in Q2 2020.
  • Thomas Steyer's portfolio value rose 7.2% quarter-over-quarter to $12.5B.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.